中国药业研发国际峰会 China Pharmaceutical R&D Summit 2011

时间: 2011/4/11 至 2011/4/13
地点:上海金茂君悦大酒店
主办单位: IBC Asia (S) Pte Ltd
发布中国药业研发国际峰会 China Pharmaceutical R&D Summit 2011的新闻报道   订阅会议
                  报名已结束,你可订阅会议
会议简介

China''''s Premier Life Science event will be coming back to Shanghai for the 6th year with a completely NEW FORMAT and NEW CONTENT!

China Pharmaceutical R&D Summit is the longest standing event in China.

View the event archives to see the outstanding track record this conference has and the past conference highlights.

The 2011 Event... 3 Focused Conferences: View the Agenda-at-a-Glance (PDF)

Clinical & Regulatory Summit

  • Understand the Regulatory Environment in China
    • Hear from a tuned-in Clinical CRO on the changing regulatory environment; a US company''''''''s insight on conducting global trials in Asia, and a leading consultant''''s strategy to bring Chinese drugs and biologics to US market.
  • Benefit from these Tried & Proven Clinical Strategies and Case Studies:
    • FIH Study in China: from IND Application to Study Completion
    • Getting Ready for Global Trials in China
    • Conducting Health Economics & Outcomes Research in China
    • Developing Risk Management Plan in Clinical Trials
    • Bridging China Data with Global Data - Global Simultaneous Development
    • Trials & Tribulations of Starting Clinical Trials in a New Geographic Region

Discovery to Preclinical Development & Partnerships

  • Hear the Latest in NCE Development from these Domestic Chinese Companies:
    • Hec Pharma, Ascentage Pharma, IMPACT Therapeutics, Sunwei Therapeutics, Argusina Shanghai, Nanjing Changao Pharmaceutical, Luye Pharma Group and TOT Shanghai
  • Get Exciting Partnering Strategies and Updates from:
    • Roche, Simcere Pharmaceuticals, Pfizer, AstraZeneca, Fosun Pharmaceutical, Synta Pharmaceuticals, DCB Taiwan, GSK and Eli Lilly

Biologics & Biosimilars Development

  • Hear Rarely-Told Stories of China''''s Biologics Development:
    • History of Licartin - a I-131 Labeled Anti-CD147 Launched in China for Liver Cancer
    • EGFR mAb - a 10-Year Development Effort
    • A 10-year Development History of Etanercept in China
    • TPO - an Innovative Biopharmaceutical Product in China
    • Interleukin-7 Receptor: A New Therapeutic Target Using Biological Approach
    • Developing Oral Insulin in China - Experiences and Lessons
  • Learn from Success Stories of Large Molecule Development from Around the World:
    • Alternatives to Antibodies - High Affinity Mirror-Image Oligonucleotides
    • Story of Abgenix: from XenoMouse to Panitumumab and Beyond
    • Development of Cell Therapy in China
    • Peptide Therapeutics in China

A never-before line-up of over 75 Speakers from international pharma, MNCs in China, and domestic Chinese pharma/biotechs will be sharing their expert opinions and experiences on clinical challenges, regulatory updates , NCE discovery efforts, preclinical partnerships, biosimilars development and more!

With shared Keynote and Plenary Sessions over 3 days, participants will be able to choose the conference of their choice or mix-and-match sessions from all 3 conferences, while taking advantage of the shared sessions and networking breaks to meet with other executives and scientists at the event.

With proven attendance from top-level executives from China''''''''s major pharma and biotech companies, this is THE MEETING PLACE to network and share experiences, meet potential partners and foster business relationships.

临床及法律规范高峰会

  • 理解中国的法律规范环境
    • 关于法律规范环境的变化、可以听取到最前线临床CRO的内容。美国企业对于在亚洲所实施的临床试验之见解、第一线顾问的中国医药品、生物制剂在美国市场所带来的策略等。
  • 学习所实行、确立的临床策略及个案研究
    • 中国的FIH研究:临床实验药的应用到研究完成
    • 中国的全球临床实验准备态势
    • 中国的医疗经济学和效果研究实施
    • 临床试验的风险管理计划决定
    • 中国的数据和国际的数据之间差距的解决 - 全球同时开发
    • 新地区展开临床试验的实行和考验

从创药到前临床开发、及合作

  • 中国国内企业的NCE开发最新趋势
    • Hec Pharma, Ascentage Pharma, IMPACT Therapeutics, Sunwei Therapeutics, Argusina Shanghai, Nanjing Changao Pharmaceutical, Luye Pharma Group and TOT Shanghai
  • 以下企业的合作策略和最新趋势
    • Roche, Simcere Pharmaceuticals, Pfizer, AstraZeneca, Fosun Pharmaceutical, Synta Pharmaceuticals, DCB Taiwan, GSK and Eli Lilly

生物制剂和生物学名药开发

  • 难能可贵的中国生物制剂开发趋势的解说
    • Licartin的历史 - 因肝癌在中国所上市的a I-131抗CD147抗体标志
    • EGFR mAb - 10年开发的计划
    • 中国的Etanercept 10年的开发历史
    • TPO ― 中国的革新生物医药品
    • Interleukin7受体:使用生物学方案的新治疗标的
    • 中国的口服胰岛素开发 - 经验和教训
  • 学习全球中大型分子开发的成功案例
    • 抗体替代物 - 高亲和性镜像寡核酸
    • Abgenix的物语:XenoMouse到Panitumumab
    • 中国细胞疗法的发展
    • 中国的缩氨酸疗法

聚集全球医药品业界超过75位的演讲者、中国国内的制药公司、生物科技公司对临床实验的相关课题及法律规范的最新趋势、NCE创药的计划、前临床阶段的合作、生物学名药开发等、独自的专门见解及体验的意见交换。

为期3天的基础演讲及总会、参加者可由3个会议中选出最适合的会议、或是组合喜好的会议参加。此外可透过共通会议及网路与其他机构的干部及科学家们进行交流。

中国的大型制药公司及生物科技企业的最高干部们也会参与本会议。期待您能莅临会场、给予意见交换及和未来的合作对象面谈、能有助于商业关系的架构。

联系方式

E-mail:

电 话:+65 6508 2401

网友评论
获取及时会议通知
»更多特别专题 >>
»更多会议资讯 >>
»更多相关会议 >>

合作伙伴